EA201791775A1 - Цистеиновая протеаза - Google Patents

Цистеиновая протеаза

Info

Publication number
EA201791775A1
EA201791775A1 EA201791775A EA201791775A EA201791775A1 EA 201791775 A1 EA201791775 A1 EA 201791775A1 EA 201791775 A EA201791775 A EA 201791775A EA 201791775 A EA201791775 A EA 201791775A EA 201791775 A1 EA201791775 A1 EA 201791775A1
Authority
EA
Eurasian Patent Office
Prior art keywords
igg
proteasis
cytestine
vivo
methods
Prior art date
Application number
EA201791775A
Other languages
English (en)
Other versions
EA035896B1 (ru
Inventor
Кристиан Челльман
София Ярнум
Эмма Нордаль
Original Assignee
Ханса Медикал Аб
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ханса Медикал Аб filed Critical Ханса Медикал Аб
Publication of EA201791775A1 publication Critical patent/EA201791775A1/ru
Publication of EA035896B1 publication Critical patent/EA035896B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6472—Cysteine endopeptidases (3.4.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6472—Cysteine endopeptidases (3.4.22)
    • C12N9/6475—Interleukin 1-beta convertase-like enzymes (3.4.22.10; 3.4.22.36; 3.4.22.63)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/22—Cysteine endopeptidases (3.4.22)
    • C12Y304/2201—Streptopain (3.4.22.10)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)

Abstract

Настоящее изобретение относится к новому полипептиду, который проявляет активность цистеиновой протеазы в отношении IgG, и к его применению in vivo и ex vivo. Применение полипептида включает способы профилактики или лечения заболеваний и состояний, опосредуемых IgG, и способы анализа IgG.
EA201791775A 2015-02-12 2016-02-12 Цистеиновая протеаза EA035896B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB201502305A GB201502305D0 (en) 2015-02-12 2015-02-12 Protein
PCT/EP2016/053054 WO2016128559A1 (en) 2015-02-12 2016-02-12 Cysteine protease

Publications (2)

Publication Number Publication Date
EA201791775A1 true EA201791775A1 (ru) 2018-02-28
EA035896B1 EA035896B1 (ru) 2020-08-27

Family

ID=52781455

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201791775A EA035896B1 (ru) 2015-02-12 2016-02-12 Цистеиновая протеаза

Country Status (28)

Country Link
US (3) US10758597B2 (ru)
EP (2) EP3256579B1 (ru)
JP (1) JP6879921B2 (ru)
KR (1) KR102524594B1 (ru)
CN (2) CN113564150A (ru)
AU (1) AU2016217801B2 (ru)
BR (1) BR112017017286A2 (ru)
CA (1) CA2976016C (ru)
CL (1) CL2017002066A1 (ru)
CO (1) CO2017009060A2 (ru)
DK (1) DK3256579T3 (ru)
EA (1) EA035896B1 (ru)
ES (1) ES2962794T3 (ru)
FI (1) FI3256579T3 (ru)
GB (1) GB201502305D0 (ru)
HR (1) HRP20231496T1 (ru)
HU (1) HUE064122T2 (ru)
IL (1) IL253939B (ru)
LT (1) LT3256579T (ru)
MX (1) MX2017010389A (ru)
MY (1) MY187486A (ru)
PL (1) PL3256579T3 (ru)
PT (1) PT3256579T (ru)
RS (1) RS64840B1 (ru)
SG (1) SG11201706349YA (ru)
SI (1) SI3256579T1 (ru)
WO (1) WO2016128559A1 (ru)
ZA (1) ZA201705114B (ru)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2795973C1 (ru) * 2019-12-06 2023-05-15 Ридженерон Фармасьютикалз, Инк. Белковые композиции против vegf и способы их получения

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201502306D0 (en) 2015-02-12 2015-04-01 Hansa Medical Ab Protein
GB201502305D0 (en) 2015-02-12 2015-04-01 Hansa Medical Ab Protein
US20210228738A1 (en) 2017-07-17 2021-07-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins
CN108410798A (zh) * 2018-03-27 2018-08-17 福建三造血技术有限公司 细胞分离用微珠洗脱液及配制方法
WO2019195449A1 (en) 2018-04-03 2019-10-10 Stridebio, Inc. Antibody-evading virus vectors
WO2020102740A2 (en) * 2018-11-16 2020-05-22 Spark Therapeutics, Inc. Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins
JP2022523679A (ja) * 2019-01-28 2022-04-26 デューク ユニバーシティ 体液性免疫を回避する組成物および方法
CA3133453A1 (en) 2019-03-21 2020-09-24 Daniel Mccoy Recombinant adeno-associated virus vectors
US20220347298A1 (en) 2019-10-04 2022-11-03 Ultragenyx Pharmaceutical Inc. Methods for improved therapeutic use of recombinant aav
JP2022551739A (ja) 2019-10-17 2022-12-13 ストライドバイオ，インコーポレイテッド ニーマン・ピック病ｃ型の治療のためのアデノ随伴ウイルスベクター
SG11202110955VA (en) 2019-12-06 2021-10-28 Regeneron Pharma Anti-vegf protein compositions and methods for producing the same
PE20221780A1 (es) * 2020-01-22 2022-11-16 Spark Therapeutics Inc Composiciones y metodos para aumentar o mejorar la transduccion de vectores de terapia genica y para eliminar o reducir inmunoglobulinas
GB202002072D0 (en) 2020-02-14 2020-04-01 Hansa Biopharma AB immunoglobulin detection and associated therapies
EP4103724A1 (en) 2020-02-14 2022-12-21 Ultragenyx Pharmaceutical Inc. Gene therapy for treating cdkl5 deficiency disorder
GB202003129D0 (en) 2020-03-04 2020-04-15 Hansa Biopharma AB Conditioning regimen for transplant of stem cells
GB202007434D0 (en) 2020-05-19 2020-07-01 Hansa Biopharma AB Methods
CN115066261A (zh) 2020-06-05 2022-09-16 上海宝济药业有限公司 一种酶和病毒的药物组合及其应用
WO2022057942A1 (zh) * 2020-09-21 2022-03-24 上海宝济药业有限公司 一种药物组合及其应用
IL301955A (en) 2020-10-07 2023-06-01 Asklepios Biopharmaceutical Inc Therapeutic delivery of an adeno-related protein-related protein (FKRP) virus for the treatment of dystroglycanopathy disorders, including limb girdle 21
JP2024515626A (ja) 2021-04-16 2024-04-10 アスクレピオス バイオファーマシューティカル， インコーポレイテッド 血液脳関門を横断し低減された液性応答を惹起する合理的ポリプロイドａａｖビリオン
EP4079848A1 (en) 2021-04-22 2022-10-26 Genovis Ab Immunoglobulin cleaving enzyme
FR3125965A1 (fr) * 2021-08-05 2023-02-10 Mc Saf Conjugués anticorps-médicament
WO2023019168A1 (en) 2021-08-11 2023-02-16 Ultragenyx Pharmaceutical Inc. Compositions and methods for treating a muscular dystrophy
CA3237815A1 (en) 2021-11-15 2023-05-19 Raghuveer RANGANATHAN Methods for enhancing adoptive cell transfer immunotherapies
EP4275701A1 (en) 2022-05-13 2023-11-15 Hansa Biopharma AB Conditioning regimen for cell transplant
EP4302770A1 (en) 2022-07-08 2024-01-10 Hansa Biopharma AB Regimen for enzymatic desensitisation
WO2024057095A1 (en) 2022-09-14 2024-03-21 Genovis Ab Mutant protease
EP4349365A1 (en) 2022-10-07 2024-04-10 Hansa Biopharma AB Co-treatment for gene therapy
CN115873833A (zh) * 2022-11-08 2023-03-31 上海泰昶生物技术有限公司 生产免疫球蛋白g降解酶的工程菌株和工艺
CN115998690A (zh) * 2022-11-10 2023-04-25 上海泰昶生物技术有限公司 包含免疫球蛋白g降解酶的冻干制剂及其制备工艺

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
CA2421278A1 (en) * 1998-03-11 1999-09-16 Genentech, Inc. Novel polypeptides and nucleic acids encoding the same
WO2002050107A2 (en) 2000-12-21 2002-06-27 Shire Biochem Inc. Streptococcus pyogenes antigens and corresponding dna fragments
GB0130228D0 (en) 2001-12-18 2002-02-06 Hansa Medica Ab Protein
PL1901773T3 (pl) 2005-06-09 2012-09-28 Hansa Medical Ab Zastosowanie proteinazy IDES (Z S. Pyogenes) do leczenia chorób autoimmunologicznych oraz odrzutów przeszczepu
GB0511769D0 (en) * 2005-06-09 2005-07-20 Hansa Medical Ab Treatment
GB0624874D0 (en) * 2006-12-13 2007-01-24 Hansa Medical Ab Treatment
WO2009033670A2 (en) 2007-09-14 2009-03-19 Genovis Ab Method and kits for dissociating fcgamma-receptor-igg complexes and for igg purification and detection
JP2011506433A (ja) 2007-12-13 2011-03-03 インターバック アーベー 改変された免疫組成物
ES2388017T3 (es) 2007-12-21 2012-10-05 Roche Glycart Ag Ensayo de estabilidad de anticuerpos
ES2535963T3 (es) 2009-02-09 2015-05-19 Roche Glycart Ag Análisis del patrón de glicosilación de inmunoglobulina
ES2612520T3 (es) 2010-05-26 2017-05-17 Intervacc Ab Vacuna contra infecciones estreptocócicas basada en proteínas recombinantes
GB201115841D0 (en) * 2011-09-13 2011-10-26 Genovis Ab Protein and method
GB201201314D0 (en) 2012-01-26 2012-03-07 Isis Innovation Composition
GB201316744D0 (en) 2013-09-20 2013-11-06 Genovis Ab Method
GB201413240D0 (en) 2014-07-25 2014-09-10 Hansa Medical Ab Method
GB201502305D0 (en) 2015-02-12 2015-04-01 Hansa Medical Ab Protein
GB201502306D0 (en) 2015-02-12 2015-04-01 Hansa Medical Ab Protein
US20210228738A1 (en) * 2017-07-17 2021-07-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2795973C1 (ru) * 2019-12-06 2023-05-15 Ридженерон Фармасьютикалз, Инк. Белковые композиции против vegf и способы их получения

Also Published As

Publication number Publication date
EP3256579B1 (en) 2023-08-30
PL3256579T3 (pl) 2024-02-26
IL253939B (en) 2020-01-30
EA035896B1 (ru) 2020-08-27
JP2018510622A (ja) 2018-04-19
AU2016217801A1 (en) 2017-08-10
CN113564150A (zh) 2021-10-29
FI3256579T3 (fi) 2023-11-13
EP4265719A1 (en) 2023-10-25
WO2016128559A1 (en) 2016-08-18
US20230302100A1 (en) 2023-09-28
ES2962794T3 (es) 2024-03-21
JP6879921B2 (ja) 2021-06-02
US20200179497A1 (en) 2020-06-11
AU2016217801B2 (en) 2022-03-17
PT3256579T (pt) 2023-11-23
CO2017009060A2 (es) 2018-01-16
MX2017010389A (es) 2017-12-07
US20180037962A1 (en) 2018-02-08
BR112017017286A2 (pt) 2018-04-17
IL253939A0 (en) 2017-10-31
CA2976016A1 (en) 2016-08-18
KR20170110153A (ko) 2017-10-10
SI3256579T1 (sl) 2024-01-31
KR102524594B1 (ko) 2023-04-21
ZA201705114B (en) 2024-01-31
CN107532158A (zh) 2018-01-02
DK3256579T3 (en) 2023-11-20
EP3256579A1 (en) 2017-12-20
HRP20231496T1 (hr) 2024-03-01
US10758597B2 (en) 2020-09-01
US11524057B2 (en) 2022-12-13
GB201502305D0 (en) 2015-04-01
CA2976016C (en) 2023-08-29
MY187486A (en) 2021-09-24
RS64840B1 (sr) 2023-12-29
CL2017002066A1 (es) 2018-02-02
HUE064122T2 (hu) 2024-03-28
SG11201706349YA (en) 2017-09-28
LT3256579T (lt) 2023-11-27

Similar Documents

Publication Publication Date Title
EA201791775A1 (ru) Цистеиновая протеаза
EA201791773A1 (ru) Цистеиновая протеаза
EA201792583A1 (ru) Способы и композиции для ингибирования взаимодействия менина с белками mll
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
EA202092435A3 (ru) Моноклональные антитела против bcma
EA201991214A1 (ru) Антитела против pd-1 и их композиции
EA201790413A1 (ru) Антитела против tigit
EA201790273A1 (ru) Флагеллиновые композиции и их применение
EA201792613A1 (ru) Модуляторы cot и способы их применения
EA201790984A1 (ru) Анти-cd79b антитела и способы их применения
EA201691582A1 (ru) Новые фармацевтические препараты
EA201691610A1 (ru) Анти-jagged1 антитела и способы применения
EA201891539A1 (ru) Соединения, ингибирующие металлоферменты
EA201692529A1 (ru) Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов
PH12019501405A1 (en) Anti-neuropilin antigen-binding proteins and methods of use thereof
EA201691541A1 (ru) Новые анти-baff антитела
EA201890747A1 (ru) Способы лечения воспалительных заболеваний
EA201792612A1 (ru) 6-аминохинолин-3-карбонитрилы в качестве модуляторов cot
EA201791467A1 (ru) Водный офтальмологический раствор
BR112017015880A2 (pt) anticorpos, usos e métodos
EA201790565A1 (ru) Композиции и способы для лечения предраковых поражений кожи
JO3565B1 (ar) الأجسام المضادة لشبيه الأنجيوبوييتين– 4 وطرق استخدامها
TW201613977A (en) Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
EA201791937A1 (ru) Противовоспалительные полипептиды
EA202191758A1 (ru) Пептиды для лечения и профилактики диабета и связанных с ним заболеваний

Legal Events

Date Code Title Description
TC4A Change in name of a patent proprietor in a eurasian patent
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM